1 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” TYK2 inhibitors show promise for treating cancer and autoimmune disorders.
4 citations
,
October 2018 in “JAMA Dermatology” Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
April 2023 in “The Egyptian Journal of Hospital Medicine” Higher Interleukin 17A levels may indicate more severe alopecia areata.
56 citations
,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
July 2024 in “Journal of Investigative Dermatology” September 2025 in “Clinical and Experimental Rheumatology” 2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
May 2026 in “SKIN The Journal of Cutaneous Medicine” Bimekizumab can improve scarring alopecia in severe psoriasis.